AbCellera Biologics (ABCL) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $12.68, +2.51% vs the prior close of $12.37.
- Volume 5.76M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ABCL rises 2.5% to $12.68. Closed at $12.68, +2.51% vs the prior close of $12.37. Day range $11.69–$12.86, opened at $11.94.
ABCL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ABCL rises 2.5% to $12.68
- Closed at $12.68, +2.51% vs the prior close of $12.37. Day range $11.69–$12.86, opened at $11.94.
- Volume was 5.76M shares, 0.8x its 50-day average of 7.17M.
- Price is +7.3% vs its 50-day average ($11.81) and +98.3% vs its 200-day average ($6.39).
- 52-week range $2.74–$15.02; today's close sits at 81% of that range, 15.6% below the 52-week high.
Oct 14, 2026 — ABCL dips 1.9% to $12.37
- Closed at $12.37, -1.90% vs the prior close of $12.61. Day range $12.26–$12.84, opened at $12.37.
- Volume was 3.06M shares, 0.4x its 50-day average of 7.19M — lighter than usual.
- Price is +5.9% vs its 50-day average ($11.68) and +94.9% vs its 200-day average ($6.35).
- 52-week range $2.74–$15.02; today's close sits at 78% of that range, 17.6% below the 52-week high.
Oct 13, 2026 — ABCL ends flat (-0.2%) to $12.61
- Closed at $12.61, -0.20% vs the prior close of $12.64. Day range $12.20–$12.72, opened at $12.53.
- Volume was 3.25M shares, 0.5x its 50-day average of 7.20M — lighter than usual.
- Price is +9.1% vs its 50-day average ($11.55) and +100.0% vs its 200-day average ($6.30).
- 52-week range $2.74–$15.02; today's close sits at 80% of that range, 16.0% below the 52-week high.
Oct 12, 2026 — ABCL rises 0.7% to $12.64
- Closed at $12.64, +0.72% vs the prior close of $12.55. Day range $12.43–$13.06, opened at $12.71.
- Volume was 5.75M shares, 0.8x its 50-day average of 7.18M.
- Price is +10.7% vs its 50-day average ($11.42) and +101.8% vs its 200-day average ($6.26).
- 52-week range $2.74–$15.02; today's close sits at 81% of that range, 15.9% below the 52-week high.
Oct 9, 2026 — ABCL jumps 4.4% to $12.55
- Closed at $12.55, +4.37% vs the prior close of $12.02. Day range $11.93–$12.79, opened at $12.03.
- Volume was 4.69M shares, 0.7x its 50-day average of 7.17M.
- Price is +11.2% vs its 50-day average ($11.28) and +101.8% vs its 200-day average ($6.22).
- 52-week range $2.74–$15.02; today's close sits at 80% of that range, 16.5% below the 52-week high.
Oct 8, 2026 — ABCL slides 6.3% to $12.02, 3 down days in a row
- Closed at $12.02, -6.31% vs the prior close of $12.83. Day range $11.89–$12.63, opened at $12.54.
- Volume was 8.52M shares, 1.2x its 50-day average of 7.12M.
- Price is +7.9% vs its 50-day average ($11.14) and +94.8% vs its 200-day average ($6.17).
- 52-week range $2.74–$15.02; today's close sits at 76% of that range, 19.9% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ABCL dips 2.4% to $12.83
- Closed at $12.83, -2.43% vs the prior close of $13.15. Day range $12.56–$13.45, opened at $12.85.
- Volume was 5.00M shares, 0.7x its 50-day average of 7.15M.
- Price is +16.5% vs its 50-day average ($11.01) and +109.3% vs its 200-day average ($6.13).
- 52-week range $2.74–$15.02; today's close sits at 82% of that range, 14.6% below the 52-week high.
Oct 6, 2026 — ABCL slides 4.6% to $13.15
- Closed at $13.15, -4.57% vs the prior close of $13.78. Day range $12.93–$14.53, opened at $14.00.
- Volume was 9.79M shares, 1.4x its 50-day average of 7.04M.
- Price is +21.1% vs its 50-day average ($10.86) and +116.2% vs its 200-day average ($6.08).
- 52-week range $2.74–$15.02; today's close sits at 85% of that range, 12.4% below the 52-week high.
Oct 5, 2026 — ABCL ends flat (+0.3%) to $13.78
- Closed at $13.78, +0.29% vs the prior close of $13.74. Day range $13.21–$13.88, opened at $13.72.
- Volume was 4.07M shares, 0.6x its 50-day average of 7.08M — lighter than usual.
- Price is +28.8% vs its 50-day average ($10.70) and +128.4% vs its 200-day average ($6.03).
- 52-week range $2.74–$15.02; today's close sits at 90% of that range, 8.2% below the 52-week high.
Oct 2, 2026 — ABCL dips 1.2% to $13.74, 3 down days in a row
- Closed at $13.74, -1.22% vs the prior close of $13.91. Day range $13.66–$14.30, opened at $14.10.
- Volume was 3.71M shares, 0.5x its 50-day average of 7.06M — lighter than usual.
- Price is +30.5% vs its 50-day average ($10.53) and +129.7% vs its 200-day average ($5.98).
- 52-week range $2.74–$15.02; today's close sits at 90% of that range, 8.5% below the 52-week high.
- That makes 3 straight losses.
ABCL latest news & SEC filings
Every SEC filing by or about ABCL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hayden Michael R bought 53,613 shares at $10.64 (≈$570.44K) on Aug 24, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Montalbano John S. bought 10,000 shares at $11.03 (≈$110.30K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Booth Andrew bought 37,200 shares at $10.32 (≈$383.90K) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hayden Michael R bought 46,387 shares at $10.37 (≈$481.03K) on Aug 12, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $4.05M (prior year $17.08M) (-76.3% vs Jun 30, 2025)
- Net income: -$55.43M (prior year -$34.73M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.12) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade ABCL
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Feb 24, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.69% (largest 9.6%).
- Liquidity: about 5.48M shares (≈$69.46M) trade per day on average.
- 52-week position: $12.68 vs a range of $2.74–$15.02 (81% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 9 open-market buys, 0 sales; latest: Michael R Hayden bought 53,613 shares on Aug 24, 2026.
- Latest filings: 8-K Aug 13, 2026; 8-K Aug 10, 2026; 8-K Aug 7, 2026.
- Share count: 306.61M shares outstanding (Aug 3, 2026), +2.6% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ABCL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 11.94 | 12.86 | 11.69 | 12.68 | 5.76M |
| Oct 14, 2026 | 12.37 | 12.84 | 12.26 | 12.37 | 3.06M |
| Oct 13, 2026 | 12.53 | 12.72 | 12.20 | 12.61 | 3.25M |
| Oct 12, 2026 | 12.71 | 13.06 | 12.43 | 12.64 | 5.75M |
| Oct 9, 2026 | 12.03 | 12.79 | 11.93 | 12.55 | 4.69M |
| Oct 8, 2026 | 12.54 | 12.63 | 11.89 | 12.02 | 8.52M |
| Oct 7, 2026 | 12.85 | 13.45 | 12.56 | 12.83 | 5.00M |
| Oct 6, 2026 | 14.00 | 14.53 | 12.93 | 13.15 | 9.79M |
| Oct 5, 2026 | 13.72 | 13.88 | 13.21 | 13.78 | 4.07M |
| Oct 2, 2026 | 14.10 | 14.30 | 13.66 | 13.74 | 3.71M |
| Oct 1, 2026 | 14.59 | 14.65 | 13.79 | 13.91 | 7.79M |
| Sep 30, 2026 | 14.78 | 15.02 | 14.56 | 14.59 | 4.86M |
| Sep 29, 2026 | 14.23 | 15.00 | 14.10 | 14.82 | 9.11M |
| Sep 28, 2026 | 12.44 | 14.23 | 12.38 | 13.92 | 7.83M |
| Sep 25, 2026 | 12.74 | 12.93 | 12.29 | 12.70 | 3.38M |
| Sep 24, 2026 | 12.02 | 12.68 | 11.78 | 12.65 | 4.99M |
| Sep 23, 2026 | 12.54 | 12.65 | 12.10 | 12.31 | 3.85M |
| Sep 22, 2026 | 12.56 | 12.97 | 12.49 | 12.65 | 4.28M |
| Sep 21, 2026 | 12.88 | 12.90 | 12.43 | 12.66 | 4.42M |
| Sep 18, 2026 | 12.73 | 12.96 | 12.37 | 12.63 | 5.43M |
About AbCellera Biologics
AbCellera Biologics (ABCL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in VANCOUVER, British Columbia, Canada. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1703057.
ABCL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carl L. G. Hansen | Chief Executive Officer | Jan 5, 2026 |
| Michael R Hayden | Director | Aug 24, 2026 |
| Veronique Lecault | Chief Technology Officer | Jan 5, 2026 |
| John S. Montalbano | Director | Aug 18, 2026 |
| Stephen Quake | Director | Jun 12, 2026 |
| Victor Sandor | Director | Jul 6, 2026 |
| Lynn Seely | Director | Jul 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Andrew Booth | Chief Financial Officer | Aug 14, 2026 |
| Carl L. G. Hansen | Chief Executive Officer | Jan 5, 2026 |
| Veronique Lecault | Chief Technology Officer | Jan 5, 2026 |
| Tryn Stimart | Chief Legal Officer | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | Michael R Hayden | Buy | 53,613 | $10.64 |
| Aug 18, 2026 | John S. Montalbano | Buy | 10,000 | $11.03 |
| Aug 14, 2026 | Andrew Booth | Buy | 37,200 | $10.32 |
| Aug 12, 2026 | Michael R Hayden | Buy | 46,387 | $10.37 |
| May 14, 2026 | John S. Montalbano | Buy | 20,000 | $4.77 |
| Feb 27, 2026 | Andrew Booth | Buy | 42,600 | $3.42 |
| Feb 27, 2026 | Holdings Ltd. Thermopylae | Buy | 38,000 | $3.44 |
| Feb 26, 2026 | Holdings Ltd. Thermopylae | Buy | 177,457 | $3.27 |
| Nov 26, 2025 | John S. Montalbano | Buy | 50,000 | $3.57 |
ABCL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $75.13M | $-146.41M | -0.49 | $-131.29M |
| Dec 31, 2024 | $28.83M | $-162.86M | -0.55 | $-108.56M |
| Dec 31, 2023 | $38.02M | $-146.40M | -0.51 | $-43.88M |
| Dec 31, 2022 | $485.42M | $158.52M | 0.50 | $277.36M |
| Dec 31, 2021 | $375.20M | $153.46M | 0.48 | $244.58M |
Latest balance sheet: total assets $1.31B, total liabilities $411.56M, cash $120.06M (as of Jun 30, 2026).
ABCL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $5.92 |
| May 11, 2026 | 8-K Item 2.02 (results) | $5.25 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $3.22 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.53 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $4.24 |
| May 8, 2025 | 8-K Item 2.02 (results) | $2.01 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $2.92 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $2.89 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 20, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ABCL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.